RxDoctor Payments Data

Insu Kong, MD

Gynecology · Westerly, RINPI 1346227188

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $918 of the $1,298 with a category attached, or 70.7%. 9 manufacturers reported payments, led by Astellas Pharma US Inc at 52.3% of the total.

$1,298in general payments, 2019–2025

Across 54 payments — averaging $24.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$679
  • Pfizer$218
  • Mayne Pharma Commercial LLC$167
  • AbbVie$120
  • Agile Therapeutics, Inc.$56
  • Sumitomo Pharma America, Inc.$17
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$91871%
  • Education$38029%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few gynecology providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$78,167
Medicare patients
542
Services billed
688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron11$13,008
PremproEstrogen,con/M-Progest Acet18$6,552
Estradiol95$2,042
ValacyclovirValacyclovir Hcl33$1,264
Solifenacin Succinate28$1,226
Oxybutynin Chloride45$754
Clobetasol Propionate28$725
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip25$602
Triamcinolone Acetonide62$550
Oxybutynin Chloride ErOxybutynin Chloride11$406
Alendronate Sodium31$356
Fluconazole39$281
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$208
Ciprofloxacin Hcl48$192
Metronidazole17$120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$679$13,00811 claims
PfizerPrempro$218$6,55218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecology providers in Rhode Islandon file to place this against a meaningful peer group, so we don't.

Other gynecology in Westerly

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →